Jun 2026 (Q2 FY26) — Aug 13, 2026
Pelthos Q2 FY26 — ZELSUVMI Drives Strong Revenue Growth Amidst Accounting Restatement
Read the full callPelthos (PTHS) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Pelthos earnings: last reported Thu, 13 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 15.6 | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. The year-earlier figure was zero or a loss, so no percentage is shown. | |
| Operating margin | -111.0 | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. | |
| Net profit | -23.4 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Price
$20.26 +0.05% · +$0.01
Performance −24.5% 1Y
1Y: $26.83 on 14 Oct 2025 → $20.26. High $37.42 (6 Nov 2025), low $18.19 (17 Feb 2026).
- Previous close
- $20.25
- 52-week range
- $18.19 – $37.42
- One year
- −26.67%
Overview
- Symbol
- PTHS
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
Pelthos earnings calls (PTHS)
Financials
What the filings say
Net profit, year on year: −579% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | — | — | 0 | 0 | 7 | 9 | 11 | 16 |
| Expenses | — | — | 2 | 3 | — | — | 24 | 33 |
| Operating profit | -2 | -2 | -2 | -3 | -15 | -12 | -13 | -17 |
| Operating margin | — | — | — | — | −207.4% | −127.8% | −120.0% | −111.0% |
| Other income | 0 | -0 | -0 | -0 | -1 | -17 | -12 | -6 |
| Interest | 0 | 0 | 0 | 0 | 1 | 1 | 2 | 2 |
| Profit before tax | -2 | -2 | -2 | -3 | -17 | -29 | -25 | -23 |
| Tax rate | — | — | 0.0% | 0.0% | 2.8% | 24.2% | 0.0% | 0.0% |
| Net profit | -2 | -2 | -2 | -3 | -16 | -22 | -25 | -23 |
| EPS ($ per share) | -2.93 | — | -3.21 | -5.29 | -5.30 | — | -7.57 | -6.62 |
| Line item | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Equity capital | 0 | 0 | 0 | 0 |
| Reserves | -6 | -14 | -21 | -65 |
| Total liabilities | 4 | 7 | 4 | 92 |
| Fixed assets | — | — | 0 | 10 |
| Total assets | 0 | 0 | 1 | 130 |
| Line item | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Cash from operations | -2 | -1 | -6 | -23 |
| Cash from investing | — | — | 0 | -5 |
| Cash from financing | 2 | 1 | 6 | 45 |
| Capital expenditure | — | — | 0 | -0 |
| Free cash flow | — | — | -6 | -23 |
Insider filings
31 filings between Nov 13, 2025 and Oct 2, 2026.
Open market
decisions to buy or sellPurchases
$1000.0K
2 purchases by 1 insider
Sales
$486.3K
24 sales by 5 insiders
79% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
Compensation
not trading decisions- 2
- Award — granted as compensation
- 1
- Tax withheld — shares kept back by the company to cover tax
Also filed: 1 disposition to issuer, 1 gift.
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Davis Todd C | $1000.0K | — | Jun 11, 2026 |
| Friedberg Ezra M | — | $325.8K | Oct 2, 2026 |
| Greenleaf Peter | — | $54.4K | Oct 2, 2026 |
| Pauls Matthew | — | $53.5K | Oct 2, 2026 |
| Francis Knuettel II | — | $40.3K | May 22, 2026 |
| Malamut Richard | — | $12.3K | Apr 2, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Oct 2, 2026 | Pauls Matthew Director | Sale 10b5-1 plan | 786 | $16.5K |
| Oct 2, 2026 | Friedberg Ezra M Director | Sale 10b5-1 plan | 558 | $11.6K |
| Oct 2, 2026 | Greenleaf Peter Director | Sale 10b5-1 plan | 797 | $16.9K |
| Jul 2, 2026 | Pauls Matthew Director | Sale 10b5-1 plan | 692 | $18.0K |
| Jul 2, 2026 | Pauls Matthew Director | Sale 10b5-1 plan | 94 | $2.6K |
| Jul 2, 2026 | Friedberg Ezra M Director | Sale 10b5-1 plan | 24 | $656 |
| Jul 2, 2026 | Friedberg Ezra M Director | Sale 10b5-1 plan | 534 | $13.9K |
| Jul 2, 2026 | Greenleaf Peter Director | Sale 10b5-1 plan | 712 | $18.5K |
| Jul 2, 2026 | Greenleaf Peter Director | Sale 10b5-1 plan | 85 | $2.3K |
| Jun 15, 2026 | Friedberg Ezra M Director | Sale 10b5-1 plan | 59 | $1.6K |
| Jun 15, 2026 | Friedberg Ezra M Director | Sale 10b5-1 plan | 224 | $6.1K |
| Jun 11, 2026 | Davis Todd C Director | Purchase | 503 | $14.4K |
| Jun 11, 2026 | Davis Todd C Director | Purchase | 35,445 | $985.5K |
| May 22, 2026 | Francis Knuettel II CFO, Treas & Secty | Disposition to issuer | 13,947 | $0 |
| May 22, 2026 | Francis Knuettel II CFO, Treas & Secty | Sale | 1,500 | $40.3K |
| May 14, 2026 | Friedberg Ezra M Director | Tax withheld 10b5-1 plan | 144 | $3.9K |
| Apr 2, 2026 | Pauls Matthew Director | Sale 10b5-1 plan | 371 | $7.9K |
| Apr 2, 2026 | Friedberg Ezra M Director | Sale 10b5-1 plan | 293 | $6.0K |
| Apr 2, 2026 | Greenleaf Peter Director | Sale 10b5-1 plan | 420 | $8.6K |
| Apr 2, 2026 | Malamut Richard Director | Sale 10b5-1 plan | 310 | $6.4K |
| Apr 2, 2026 | Malamut Richard Director | Sale 10b5-1 plan | 280 | $6.0K |
| Apr 2, 2026 | Friedberg Ezra M Director | Sale 10b5-1 plan | 265 | $5.7K |
| Apr 2, 2026 | Greenleaf Peter Director | Sale 10b5-1 plan | 377 | $8.1K |
| Apr 2, 2026 | Pauls Matthew Director | Sale 10b5-1 plan | 415 | $8.5K |
| Dec 23, 2025 | Einhorn Andrew J. Director | Award | 12,000 | — |
| Dec 10, 2025 | Pauls Matthew Director | Gift | 9,542 | $0 |
| Nov 25, 2025 | Friedberg Ezra M Director | Sale | 1 | $29 |
| Nov 25, 2025 | Friedberg Ezra M Director | Sale | 5,999 | $168.0K |
| Nov 25, 2025 | Friedberg Ezra M Director | Sale | 2,000 | $56.3K |
| Nov 25, 2025 | Friedberg Ezra M Director | Sale | 2,000 | $56.0K |
| Nov 13, 2025 | Malamut Richard Director | Award | 2,454 | $0 |
| Oct 2, 2025 | Pauls Matthew Director | Option exercise | 2,123 | $0 |
| Jul 2, 2025 | Davis Todd C Director | Award | 19,108 | $0 |
| Jul 2, 2025 | Francis Knuettel II CFO, Treas & Secty | Award | 33,472 | $0 |
| Jul 2, 2025 | Friedberg Ezra M Director | Award | 19,108 | $0 |
| Jul 2, 2025 | Plesha Scott M. CEO and President | Award | 83,678 | $0 |
| Jul 2, 2025 | Greenleaf Peter Director | Award | 25,478 | $0 |
| Jul 2, 2025 | Rangarao Sai Chief Commercial Officer | Award | 30,518 | $0 |
| Jul 2, 2025 | Pauls Matthew Director | Award | 25,478 | $0 |
| Jul 2, 2025 | Baxter Richard B Director | Award | 19,108 | $0 |
| Jul 2, 2025 | Malamut Richard Director | Award | 19,108 | $0 |
| Jul 1, 2025 | LIGAND PHARMACEUTICALS INC 10% owner | Conversion | 1,500,000 | $15.00M |
| Jul 1, 2025 | Davis Todd C Director | Conversion | 1,500,000 | $15.00M |
| Jul 1, 2025 | Francis Knuettel II Chief Financial Officer | Conversion | 10,000 | $100.0K |
| Jul 1, 2025 | Friedberg Ezra M Director | Conversion | 40,000 | $400.0K |
| Jul 1, 2025 | Friedberg Ezra M Director | Conversion | 40,000 | $400.0K |
| Nov 13, 2024 | Davis Todd C Director | Award | 4,961 | $0 |
| Nov 13, 2024 | Friedberg Ezra M Director | Award | 2,454 | $0 |
| Sep 13, 2024 | Francis Knuettel II CEO, Pres., CFO, Treas & Secty | Purchase | 3,500 | $3.4K |
| Sep 12, 2024 | Francis Knuettel II CEO, Pres., CFO, Treas & Secty | Purchase | 1,700 | $1.6K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for Pelthos Therapeutics Inc.
Free account. Everything above stays public.
Write why you follow Pelthos Therapeutics Inc. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading